{"name":"Gilead Sciences, Inc.","slug":"gilead","ticker":"GILD","exchange":"NASDAQ","domain":"gilead.com","description":"Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Gilead is a member of the Nasdaq-100 and the S&P 100.","hq":"Foster City, CA","founded":0,"employees":"17000","ceo":"Daniel O\\\\\\\\\\\\\\","sector":"Big Pharma","stockPrice":133.15,"stockChange":0.1,"stockChangePercent":0.08,"marketCap":"$165.3B","metrics":{"revenue":29735999488,"revenueGrowth":4.4,"grossMargin":79.4,"rdSpend":9106000000,"netIncome":8510000000,"cash":9816999936,"dividendYield":2.47,"peRatio":18.1,"fiscalYear":"FY2020"},"revenueBreakdown":[{"name":"Biktarvy","genericName":"BICTEGRAVIR","slug":"bictegravir","revenue":13400000000,"yoyGrowth":0,"percentOfTotal":59.3},{"name":"Vemlidy","genericName":"TENOFOVIR ALAFENAMIDE","slug":"tenofovir-alafenamide","revenue":2800000000,"yoyGrowth":0,"percentOfTotal":12.4},{"name":"Emtriva","genericName":"EMTRICITABINE","slug":"emtricitabine","revenue":2400000000,"yoyGrowth":0,"percentOfTotal":10.6},{"name":"Veklury","genericName":"remdesivir","slug":"remdesivir","revenue":2200000000,"yoyGrowth":0,"percentOfTotal":9.7},{"name":"Sunlenca","genericName":"LENACAPAVIR","slug":"lenacapavir","revenue":1600000000,"yoyGrowth":0,"percentOfTotal":7.1},{"name":"Livdelzi","genericName":"SELADELPAR","slug":"seladelpar","revenue":200000000,"yoyGrowth":0,"percentOfTotal":0.9}],"timeline":[{"date":"1996-01-01","label":"Vistide first approved","drug":"Vistide","drugSlug":"cidofovir","type":"approval","sentiment":"positive"},{"date":"2002-01-01","label":"Hepsera first approved","drug":"Hepsera","drugSlug":"adefovir-dipivoxil","type":"approval","sentiment":"positive"},{"date":"2003-01-01","label":"Emtriva first approved","drug":"Emtriva","drugSlug":"emtricitabine","type":"approval","sentiment":"positive"},{"date":"2007-01-01","label":"Letairis first approved","drug":"Letairis","drugSlug":"ambrisentan","type":"approval","sentiment":"positive"},{"date":"2012-01-01","label":"Vitekta first approved","drug":"Vitekta","drugSlug":"elvitegravir","type":"approval","sentiment":"positive"},{"date":"2012-01-01","label":"Tybost first approved","drug":"Tybost","drugSlug":"cobicistat","type":"approval","sentiment":"positive"},{"date":"2015-01-01","label":"Vemlidy first approved","drug":"Vemlidy","drugSlug":"tenofovir-alafenamide","type":"approval","sentiment":"positive"},{"date":"2018-01-01","label":"Biktarvy first approved","drug":"Biktarvy","drugSlug":"bictegravir","type":"approval","sentiment":"positive"},{"date":"2020-01-01","label":"Veklury first approved","drug":"Veklury","drugSlug":"remdesivir","type":"approval","sentiment":"positive"},{"date":"2026-01-01","label":"Livdelzi first approved","drug":"Livdelzi","drugSlug":"seladelpar","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"Truvada patent cliff ($1.3B at risk)","drug":"Truvada","type":"patent_expiry","sentiment":"negative"},{"date":"2030-06-01","label":"Biktarvy patent cliff ($2.5B at risk)","drug":"Biktarvy","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":18600000000,"percentOfTotal":82.3,"drugCount":5,"colorKey":"oncology","drugs":[{"name":"Biktarvy","genericName":"BICTEGRAVIR","slug":"bictegravir","indication":"Human immunodeficiency virus infection","status":"marketed","revenue":13400000000},{"name":"Vemlidy","genericName":"TENOFOVIR ALAFENAMIDE","slug":"tenofovir-alafenamide","indication":"Human immunodeficiency virus infection","status":"marketed","revenue":2800000000},{"name":"Emtriva","genericName":"EMTRICITABINE","slug":"emtricitabine","indication":"Human immunodeficiency virus infection","status":"marketed","revenue":2400000000},{"name":"Jyseleca","genericName":"FILGOTINIB","slug":"filgotinib","indication":"Rheumatoid arthritis","status":"marketed"},{"name":"Vistide","genericName":"CIDOFOVIR","slug":"cidofovir","indication":"Acyclovir-Resistant Mucocutaneous HSV in Immunocompromised Patients","status":"marketed"}]},{"name":"Respiratory","slug":"respiratory","revenue":2200000000,"percentOfTotal":9.7,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Veklury","genericName":"remdesivir","slug":"remdesivir","indication":"Disease caused by Severe acute respiratory syndrome coronavirus 2","status":"marketed","revenue":2200000000}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":1600000000,"percentOfTotal":7.1,"drugCount":4,"colorKey":"cardiovascular","drugs":[{"name":"Sunlenca","genericName":"LENACAPAVIR","slug":"lenacapavir","indication":"Multidrug resistant HIV-1 infection","status":"marketed","revenue":1600000000},{"name":"Hepsera","genericName":"ADEFOVIR DIPIVOXIL","slug":"adefovir-dipivoxil","indication":"Chronic type B viral hepatitis","status":"marketed"},{"name":"Vitekta","genericName":"ELVITEGRAVIR","slug":"elvitegravir","indication":"Treatment of HIV-1 Infection","status":"marketed"},{"name":"Hepsera","genericName":"Hepsera","slug":"hepsera","indication":"Chronic type B viral hepatitis","status":"marketed"}]},{"name":"Other","slug":"other","revenue":200000000,"percentOfTotal":0.9,"drugCount":12,"colorKey":"neuroscience","drugs":[{"name":"Livdelzi","genericName":"SELADELPAR","slug":"seladelpar","indication":"Primary Biliary Cholangitis (PBC)","status":"marketed","revenue":200000000},{"name":"COPE","genericName":"COPE","slug":"cope","indication":"Other","status":"marketed"},{"name":"GS-7340","genericName":"GS-7340","slug":"gs-7340","indication":"Other","status":"phase_1"},{"name":"CILO","genericName":"CILO","slug":"cilo","indication":"Other","status":"marketed"},{"name":"Current HAART regimen","genericName":"Current HAART regimen","slug":"current-haart-regimen","indication":"Other","status":"marketed"},{"name":"EFV+3TC+TDF","genericName":"EFV+3TC+TDF","slug":"efv-3tc-tdf","indication":"Other","status":"marketed"},{"name":"EFV+TDF","genericName":"EFV+TDF","slug":"efv-tdf","indication":"Other","status":"marketed"},{"name":"GS-0151","genericName":"GS-0151","slug":"gs-0151","indication":"Other","status":"phase_1"},{"name":"GS-0201","genericName":"GS-0201","slug":"gs-0201","indication":"Other","status":"phase_1"},{"name":"GS-5745","genericName":"GS-5745","slug":"gs-5745","indication":"Other","status":"phase_1"},{"name":"Harvoni","genericName":"Harvoni","slug":"harvoni","indication":"Other","status":"marketed"},{"name":"MBX-8025","genericName":"MBX-8025","slug":"mbx-8025","indication":"Other","status":"phase_2"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"infectious","drugs":[{"name":"Letairis","genericName":"AMBRISENTAN","slug":"ambrisentan","indication":"Pulmonary arterial hypertension","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"respiratory","drugs":[{"name":"Tybost","genericName":"COBICISTAT","slug":"cobicistat","indication":"Human immunodeficiency virus infection","status":"marketed"}]}],"pipeline":[{"name":"Biktarvy","genericName":"BICTEGRAVIR","slug":"bictegravir","phase":"marketed","mechanism":"Biktarvy works by binding to the integrase enzyme, preventing the HIV virus from integrating its genetic material into the host cell's DNA.","indications":["Human immunodeficiency virus infection"],"catalyst":""},{"name":"Vemlidy","genericName":"TENOFOVIR ALAFENAMIDE","slug":"tenofovir-alafenamide","phase":"marketed","mechanism":"Vemlidy works by inhibiting the HIV reverse transcriptase enzyme, preventing viral replication.","indications":["Human immunodeficiency virus infection"],"catalyst":""},{"name":"Emtriva","genericName":"EMTRICITABINE","slug":"emtricitabine","phase":"marketed","mechanism":"Emtriva works by blocking the reverse transcriptase enzyme, which is necessary for HIV to replicate.","indications":["Human immunodeficiency virus infection"],"catalyst":""},{"name":"Veklury","genericName":"remdesivir","slug":"remdesivir","phase":"marketed","mechanism":"Remdesivir is an antiviral nucleotide analog RNA polymerase inhibitor with activity against SARS-CoV-2.","indications":["Disease caused by Severe acute respiratory syndrome coronavirus 2"],"catalyst":""},{"name":"Sunlenca","genericName":"LENACAPAVIR","slug":"lenacapavir","phase":"marketed","mechanism":"Sunlenca works by binding to a specific site on the HIV-1 protease, preventing the virus from replicating.","indications":["Multidrug resistant HIV-1 infection"],"catalyst":""},{"name":"Livdelzi","genericName":"SELADELPAR","slug":"seladelpar","phase":"marketed","mechanism":"Livdelzi works by inhibiting the activity of a specific enzyme involved in the progression of liver disease.","indications":["Primary Biliary Cholangitis (PBC)"],"catalyst":""},{"name":"Jyseleca","genericName":"FILGOTINIB","slug":"filgotinib","phase":"marketed","mechanism":"Tyrosine-protein kinase JAK1","indications":["Rheumatoid arthritis","Ulcerative colitis"],"catalyst":""},{"name":"COPE","genericName":"COPE","slug":"cope","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"GS-7340","genericName":"GS-7340","slug":"gs-7340","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Hepsera","genericName":"ADEFOVIR DIPIVOXIL","slug":"adefovir-dipivoxil","phase":"marketed","mechanism":"Hepsera works by mimicking a building block of DNA, which it uses to trick the Hepatitis B Virus into incorporating faulty genetic material, ultimately halting its replication.","indications":["Chronic type B viral hepatitis"],"catalyst":""},{"name":"Vitekta","genericName":"ELVITEGRAVIR","slug":"elvitegravir","phase":"marketed","mechanism":"Vitekta blocks the integrase enzyme, preventing HIV from replicating.","indications":["Treatment of HIV-1 Infection","Replacement of Current Antiretroviral Regimen"],"catalyst":""},{"name":"CILO","genericName":"CILO","slug":"cilo","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Current HAART regimen","genericName":"Current HAART regimen","slug":"current-haart-regimen","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"EFV+3TC+TDF","genericName":"EFV+3TC+TDF","slug":"efv-3tc-tdf","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"EFV+TDF","genericName":"EFV+TDF","slug":"efv-tdf","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"GS-0151","genericName":"GS-0151","slug":"gs-0151","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"GS-0201","genericName":"GS-0201","slug":"gs-0201","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"GS-5745","genericName":"GS-5745","slug":"gs-5745","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Harvoni","genericName":"Harvoni","slug":"harvoni","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Hepsera","genericName":"Hepsera","slug":"hepsera","phase":"marketed","mechanism":"DNA polymerase subunit gamma-1, Capsid protein, Protein P","indications":["Chronic type B viral hepatitis"],"catalyst":""},{"name":"Letairis","genericName":"AMBRISENTAN","slug":"ambrisentan","phase":"marketed","mechanism":"Endothelin-1 receptor","indications":["Pulmonary arterial hypertension"],"catalyst":""},{"name":"MBX-8025","genericName":"MBX-8025","slug":"mbx-8025","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Tybost","genericName":"COBICISTAT","slug":"cobicistat","phase":"marketed","mechanism":"Tybost works by blocking the enzyme Cytochrome P450 3A, which is responsible for breaking down many other medications.","indications":["Human immunodeficiency virus infection","Malignant Melanoma with BRAF V600E Mutation"],"catalyst":""},{"name":"Vistide","genericName":"CIDOFOVIR","slug":"cidofovir","phase":"marketed","mechanism":"Small molecule","indications":["Acyclovir-Resistant Mucocutaneous HSV in Immunocompromised Patients","CMV Retinitis in AIDS Patients"],"catalyst":""}],"recentEvents":[{"date":"2024-02-27","type":"earnings","headline":"Gilead Sciences Reports Fourth-Quarter and Full-Year 2023 Financial Results","summary":"Gilead Sciences, Inc. (GILD) today reported its financial results for the fourth quarter and full year 2023. The company reported net income of $4.8 billion and revenue of $24.3 billion for the full year.","drugName":"","sentiment":"neutral"},{"date":"2023-12-22","type":"deal","headline":"Gilead Sciences and Galapagos NV Announce Collaboration to Develop and Commercialize Novel Therapies for Fungal Infections","summary":"Gilead Sciences, Inc. (GILD) and Galapagos NV today announced a collaboration to develop and commercialize novel therapies for fungal infections. The collaboration will leverage Gilead's expertise in antifungal development and Galapagos' capabilities in drug discovery.","drugName":"","sentiment":"positive"},{"date":"2023-11-01","type":"regulatory","headline":"FDA Approves Gilead Sciences' Veklury for the Treatment of COVID-19","summary":"The U.S. Food and Drug Administration (FDA) today approved Veklury (remdesivir) for the treatment of COVID-19. Veklury is an antiviral medication developed by Gilead Sciences, Inc. (GILD).","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxNNExIdWhWVGpZdWxNQWxYTjRBR1M4ck1FcG1neFR5dzUwVG5maG5xOFZWbVpMU1ctOHRlaG84TzhsV1ppdzR6ZFJFQ1pUOTQwUnJpaVBDWnFnWmRsb1h3R2lsamdHa1pMZ01zUmNHdzBRSWRQZWJPTC1wejhVbjJ2NzNLZkt5VnJUdWNpTURHbno?oc=5","date":"2026-04-07","type":"deal","source":"Contract Pharma","summary":"Gilead Sciences Agrees to Acquire Tubulis - Contract Pharma","headline":"Gilead Sciences Agrees to Acquire Tubulis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxQRHo1M3RfRHM0d2ljeVJEX1ZyT0hsdUd3N0JvazZxb0xsUzM0QVZOOHVZQlZiZFA3YnFUT2pfMHlib3BXVjR1bTFvU3JjNnJsNDAzS0ZweFVFZlFIcDZvUUxveF83UkpMc0twdXp5VC10ZTY5UlByTHhTWkFmdHdBeUZybjAyQnowVkduSXBhamF1Wm1SUm1zYlduTmMxem84N01sR3ZjS3NKUEFiYWc?oc=5","date":"2026-03-27","type":"deal","source":"Fierce Pharma","summary":"Fierce Pharma Asia—Takeda’s $1.3B reorg; India’s GLP-1 floodgates; Gilead’s $2.2B buy of a China NewCo - Fierce Pharma","headline":"Fierce Pharma Asia—Takeda’s $1.3B reorg; India’s GLP-1 floodgates; Gilead’s $2.2B buy of a China NewCo","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxQQ0FPa3VrQTNwMk9fWjExcm5SQXhxZ0tWSXpjcG5aSVNHcGc3UDhCVW1TQjVZNWw2eG9paW1VQmdDMGFQR3YxVkFYbGdQeG5HdVM5dkd4UVF6Z2NUTk9NaXluZ1JlQ2llTFlLcGIzNy1xX3FwMkRkX0E2ZjRqYWJ0ZUhNQlNmRDFIMVFGeEFfY2Noc2V6dy1qM2pndVVjZ3JtYWlsTm5wQzc0dDg?oc=5","date":"2026-03-24","type":"deal","source":"Pharmaceutical Executive","summary":"Gilead Sciences Enters $2.1 Billion Definitive Agreement to Acquire Ouro Medicines - Pharmaceutical Executive","headline":"Gilead Sciences Enters $2.1 Billion Definitive Agreement to Acquire Ouro Medicines","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxNdTdNajFFMEhvdnBEOV9YZGdLa0xKVldGUTRGWVM2c1g3aTgzaUlWS0l1SXp4eVdDSU5IZURRN3BsT01LNmQzUjYyVTFZQlREYlJNWUFFZTQ5X1QtZHBfbTBmRDJLZWZVV1NmdGpvekJKQVNBVDRXVHNPMF9XVjJ2UjlMeGVzQkFYSktXM1AxSHdlOFJsTVIwbWhuYnRraE9KdkJIUmx2RlpoTWo3bVBEdWc2aWlmYXh3dW1mSmVPVEJLQjM3?oc=5","date":"2026-03-13","type":"pipeline","source":"Fierce Pharma","summary":"'Manufacturing is access': How Gilead's early production moves set PrEP med Yeztugo up for success - Fierce Pharma","headline":"'Manufacturing is access': How Gilead's early production moves set PrEP med Yeztugo up for success","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxPbnZxcmhlTVcxTUQ1UU5jNEpnX3hGX0RIcjk1S3Q2WDRUU1UxbTMyODJCZ0NWWlI2WDVSSGVtelJFNHJ5cnF1Y3o1ZVByOUpxYjVWQTZoWE5ZT19GalpIT0RwTzVpYWNYN29Bcy12eVlmZTJQN1VYSXZIREl2NldRdGN6YUtYb0NCZktwbmhlZHZOTGJJem1Sc2VoX21hS0hqWkJHV1RKSlQ?oc=5","date":"2026-02-23","type":"deal","source":"BioPharma Dive","summary":"Gilead to buy Arcellx in $7.8B wager on multiple myeloma cell therapy - BioPharma Dive","headline":"Gilead to buy Arcellx in $7.8B wager on multiple myeloma cell therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxPNG9yZkMtMThuajdpSGFoN3JfVHpYaUxsaGtIR0pPT095bnp2UllMOTkyNVR1YVBneWRaVmctU1ZCNGd0WFJfdnYwZFhkWkFKQjEyamFneXpOLTQtZXQxMjRTSGJSMWQ2OHA5TzhJa1AtdjJacjhrWHJmeWNwWEJmRw?oc=5","date":"2026-01-31","type":"pipeline","source":"Yahoo Finance","summary":"UBS Turns More Bullish on Gilead Sciences, Inc. (GILD) Amid Positive Pharma Sector Outlook - Yahoo Finance","headline":"UBS Turns More Bullish on Gilead Sciences, Inc. (GILD) Amid Positive Pharma Sector Outlook","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiW0FVX3lxTFBoZWw2dFVDanRVQlFjc2J2YUkxWExrcnhUUVV1UWdxakx2endPZzlzWkpDS3BpV1NMRDItVk5yaUFFUVdPY3dSVFZuWFVXVUZOQ3VaQ0FPSk5wUVE?oc=5","date":"2026-01-30","type":"pipeline","source":"Oncodaily","summary":"Daniel O’Day: Turning Innovation Into Impact With Gilead Sciences and Kite Pharma Teams - Oncodaily","headline":"Daniel O’Day: Turning Innovation Into Impact With Gilead Sciences and Kite Pharma Teams","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxNODRqUnAyM3k5TnY0aHc0MmhWZC1PT2lQU2NWbnppZk1fdi14dm5WRmY0bkdMRkkyYzRxNFR5bTVPWDBSeXB0dzJNOWlnZ3V2RWZyMjBKNERCNFZ3QnZhNGNwX0ZKMS1SQ3JvYUFHOEg3YjdIX3FVdDF4Q1FqbUdCbUYtYk9Ydw?oc=5","date":"2025-12-26","type":"deal","source":"Pharmaceutical Technology","summary":"Gilead Sciences to acquire Repare’s RP-3467 - Pharmaceutical Technology","headline":"Gilead Sciences to acquire Repare’s RP-3467","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxQNXZHMUJPaEZ0V1E1cGJJLUxFVmZZZ2d0VkZMX3A4MjJlUFdZb2tmQldpUGtJbDlhc0hHOHdWOXJHVEp4TjZOYk5FY3VTWjJ4NGl5VEtCekVVWDJYZXUxNG40RnMyakJpZFphZzJMMG83eW9DRXRJY2xPbXNYVU5SNXdzWkl1YXVtVG9lM00yNGctZDEt?oc=5","date":"2025-09-29","type":"deal","source":"Fierce Biotech","summary":"Gilead pumps up virology pipeline with drug transporter deal - Fierce Biotech","headline":"Gilead pumps up virology pipeline with drug transporter deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxQQjZCdkVmSnQ1bHNJVFJzMUtQNTNxU3U4ZXBXc04tZnlkekdsMnRxUjdPcTAxS1dEdXc1UUdqQXExTG1CT2lrd3Yxd3hXSkxlMHBZNXMtOTFzdDBvZVpPNXZWbWlYS3B3dko0OWZ3cGlEaUljaGJWTWx0MlBIck0za0l0blZYS3lSYm9TMVdLRzJHSTBDTjFwM3RKY1NBTURYRk1SNG5qWUJac1NwVE1GRDJuUTFmOTZJT1RoZmMxTVdqOTBnbWRpbzE5VHFGTUJjcnN3?oc=5","date":"2025-09-29","type":"pipeline","source":"prnewswire.com","summary":"Health Hope Pharma Enters into Exclusive Licensing Agreement with Gilead Sciences - prnewswire.com","headline":"Health Hope Pharma Enters into Exclusive Licensing Agreement with Gilead Sciences","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxQNkFQNVUxYWlJQU1YZlpBSXFrUEotWnBHU1hEQ0lmcU0wR25nX3hETGkxV2M2UVN5NW5ZNHdjYS03NVAyUTBWVjJIZkRyUmR3cXBfUVFjUHVDWDFhYlZSTEhqTlFyenIyNXphZXcyVzNLMml4dlhxeG1qa1dWck1uY1J0SmdaeW9NQ3JmOHNZcnpBR1V2cVAyaXZIXzcxYkFWR3FyTi01NWtFaGE4WGZtbFRlOEQ2ajFJdGpRQ2FDbnBXd3RwbVZob2lJQzZVQWVXOU9VWkxscw?oc=5","date":"2025-09-15","type":"pipeline","source":"California State Portal | CA.gov","summary":"Global biotech leaders Amgen and Gilead announcing expansions in California, the #1 state for life sciences - California State Portal | CA.gov","headline":"Global biotech leaders Amgen and Gilead announcing expansions in California, the #1 state for life sciences - California","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxOZTR2M3N6ZU1JNnlmdlRqNGFwQkItSkp4azI1aGF1b0k3UnQzZWd0SjFmZnJPMXF3ZkJwNXROd2VvZUsxckh0UjRrNHRzS1BMU2MzcmhYNWI3NjNhVzBpMTBQYW9jbWNZbHloeE1YbF8zTlA3c3BpTVJsWUFfSy1LV05VY0NSMHNkV3hBNTBmT0dsazdSbXBFQzJDdUhQTExIQ2t6Nk13ZW4xYVlzMkdCMmJxTy1mMy1yOG1ydllqLTJqbU5GdERja1hiaURhaktpS0VKdnYxYkRxVU9iaE1pdDdvU2ZyZms?oc=5","date":"2025-09-03","type":"pipeline","source":"Reuters","summary":"Gilead starts building manufacturing hub under $32 billion planned US investments - Reuters","headline":"Gilead starts building manufacturing hub under $32 billion planned US investments","sentiment":"neutral"}],"patents":[{"drugName":"Truvada","drugSlug":"emtricitabine/tenofovir-disoproxil-fumarate","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":1300000000},{"drugName":"Biktarvy","drugSlug":"bictegravir/emtricitabine/tenofovir-alafenamide","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":2500000000}],"drugCount":24,"phaseCounts":{"marketed":19,"phase_1":4,"phase_2":1},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Johnson & Johnson","Merck & Co.","Pfizer Inc."],"therapeuticFocus":["HIV/AIDS","Hepatitis B and C","Fungal infections"],"financials":{"source":"sec_edgar+yahoo","revenue":24689000000,"revenuePeriod":"2020-12-31","revenueHistory":[{"value":24689000000,"period":"2020-12-31"},{"value":7421000000,"period":"2020-12-31"},{"value":6577000000,"period":"2020-09-30"},{"value":5143000000,"period":"2020-06-30"},{"value":5548000000,"period":"2020-03-31"}],"grossProfit":23208000000,"grossProfitHistory":[{"period":"2025-12-31","value":23208000000},{"period":"2024-12-31","value":22503000000},{"period":"2023-12-31","value":20618000000},{"period":"2022-12-31","value":21624000000}],"rdSpend":9106000000,"rdSpendHistory":[{"period":"2025-12-31","value":5799000000},{"period":"2024-12-31","value":5907000000},{"period":"2023-12-31","value":5718000000},{"period":"2022-12-31","value":4977000000}],"sgaSpend":5708000000,"operatingIncome":11701000000,"operatingIncomeHistory":[{"period":"2025-12-31","value":11701000000},{"period":"2024-12-31","value":10596000000},{"period":"2023-12-31","value":8838000000},{"period":"2022-12-31","value":10974000000}],"netIncome":8510000000,"netIncomeHistory":[{"period":"2025-12-31","value":8510000000},{"period":"2024-12-31","value":480000000},{"period":"2023-12-31","value":5665000000},{"period":"2022-12-31","value":4592000000}],"eps":6.78,"epsHistory":[{"period":"2025-12-31","value":6.78},{"period":"2024-12-31","value":0.38},{"period":"2023-12-31","value":4.5},{"period":"2022-12-31","value":3.64}],"cash":7564000000,"cashHistory":[{"period":"2025-12-31","value":7564000000},{"period":"2024-12-31","value":9991000000},{"period":"2023-12-31","value":6085000000},{"period":"2022-12-31","value":5412000000}],"totalAssets":59023000000,"totalLiabilities":36405000000,"totalDebt":24936000000,"equity":22702000000,"operatingCashflow":10019000000,"operatingCashflowHistory":[{"period":"2025-12-31","value":10019000000},{"period":"2024-12-31","value":10828000000},{"period":"2023-12-31","value":8006000000},{"period":"2022-12-31","value":9072000000}],"capex":-563000000,"capexHistory":[{"period":"2025-12-31","value":-563000000},{"period":"2024-12-31","value":-523000000},{"period":"2023-12-31","value":-585000000},{"period":"2022-12-31","value":-728000000}],"freeCashflow":9456000000,"dividendsPaid":-4003000000,"buybacks":-1922000000,"employees":17000,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":1728000000,"ebit":2333000000,"ebitda":3020000000,"period":"2025-12-31","revenue":7924000000,"epsBasic":1.76,"netIncome":2183000000,"rdExpense":1584000000,"epsDiluted":1.74,"grossProfit":6300000000,"operatingIncome":2988000000},{"sga":1357000000,"ebit":3897000000,"ebitda":4583000000,"period":"2025-09-30","revenue":7769000000,"epsBasic":2.46,"netIncome":3052000000,"rdExpense":1346000000,"epsDiluted":2.43,"grossProfit":6200000000,"operatingIncome":3497000000},{"sga":1365000000,"ebit":2683000000,"ebitda":3374000000,"period":"2025-06-30","revenue":7081000000,"epsBasic":1.57,"netIncome":1960000000,"rdExpense":1491000000,"epsDiluted":1.56,"grossProfit":5580000000,"operatingIncome":2724000000},{"sga":1258000000,"ebit":1909000000,"ebitda":2605000000,"period":"2025-03-31","revenue":6667000000,"epsBasic":1.06,"netIncome":1315000000,"rdExpense":1379000000,"epsDiluted":1.04,"grossProfit":5127000000,"operatingIncome":2490000000},{"sga":1907000000,"ebit":2416000000,"ebitda":3109000000,"period":"2024-12-31","revenue":7569000000,"epsBasic":1.43,"netIncome":1783000000,"rdExpense":1641000000,"epsDiluted":1.42,"grossProfit":5988000000,"operatingIncome":2440000000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":133.15,"previousClose":133.05,"fiftyTwoWeekHigh":157.29,"fiftyTwoWeekLow":97.86,"fiftyTwoWeekRange":"97.86 - 157.29","fiftyDayAverage":137.99,"twoHundredDayAverage":127.69,"beta":0.33,"enterpriseValue":177463869440,"forwardPE":13.8,"priceToBook":7.28,"priceToSales":5.56,"enterpriseToRevenue":5.97,"enterpriseToEbitda":12.04,"pegRatio":0.37,"ebitda":14737999872,"ebitdaMargin":49.6,"freeCashflow":7934125056,"operatingCashflow":10805999616,"totalDebt":22173999104,"debtToEquity":94.6,"currentRatio":1.97,"returnOnAssets":13.3,"returnOnEquity":43.4,"analystRating":"1.7 - Buy","recommendationKey":"buy","numberOfAnalysts":28,"targetMeanPrice":157.96,"targetHighPrice":180,"targetLowPrice":122,"dividendRate":3.28,"payoutRatio":0.43,"fiveYearAvgDividendYield":3.65,"exDividendDate":1781481600,"insiderHeldPercent":0.1,"institutionHeldPercent":92.8,"sharesOutstanding":1241569874,"floatShares":1238826005,"sharesShort":23051059,"shortRatio":4.22,"shortPercentOfFloat":1.9,"epsTrailing":7.34,"epsForward":9.62,"revenuePerShare":23.92,"bookValue":18.29,"officers":[{"age":60,"name":"Mr. Daniel P.  O'Day","title":"Chairman & CEO"},{"age":55,"name":"Mr. Andrew D. Dickinson","title":"Chief Financial Officer"},{"age":55,"name":"Ms. Johanna  Mercier","title":"Chief Commercial & Corporate Affairs Officer"},{"age":56,"name":"Dr. Dietmar P. Berger M.D., Ph.D.","title":"Chief Medical Officer"},{"age":46,"name":"Ms. Erin E. Burkhart","title":"Senior VP, Controller & Principal Accounting Officer"},{"age":null,"name":"Ms. Jacquie  Ross C.F.A.","title":"Senior Vice President of Treasury & Investor Relations"},{"age":50,"name":"Ms. Keeley M. Cain Wettan","title":"Executive VP and General Counsel of Legal & Compliance"},{"age":48,"name":"Ms. Jyoti K. Mehra","title":"Executive Vice President of Human Resources"}],"industry":"Drug Manufacturers - General","irWebsite":"http://investors.gilead.com/phoenix.zhtml?c=69964&p=irol-irhome","website":"https://www.gilead.com","phone":"650 574 3000"}}